ReviewWorld journal of gastroenterology2010
Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.
Review in World journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.British journal of cancer · 2015Pooled it
- Transcriptomic Profiling of Laser Capture Microdissected FFPE Esophageal Tissues Identifies Candidate Genes and Pathways Associated with Esophageal Adenocarcinoma.International journal of molecular sciences · 2026Article
- Epigenetic biomarkers and the progression of Barrett's oesophagus to oesophageal adenocarcinoma: a systematic review protocol.Systematic reviews · 2026Article
- Molecules involved in the development of Barrett's esophagus phenotype in chronic eosinophilic esophagitis.American journal of physiology. Gastrointestinal and liver physiology · 2022Article
- Profiles of autophagy-related genes in esophageal adenocarcinoma.BMC cancer · 2020Article
- Towards screening Barrett's oesophagus: current guidelines, imaging modalities and future developments.Clinical journal of gastroenterology · 2020Review
- Barrett's oesophagus: Current controversies.World journal of gastroenterology · 2017Review
- From blood to breath: New horizons for esophageal cancer biomarkers.World journal of gastroenterology · 2016Review
- Combination of three-gene immunohistochemical panel and magnetic resonance imaging-detected extramural vascular invasion to assess prognosis in non-advanced rectal cancer patients.World journal of gastroenterology · 2016Article
- Article
- Golgi phosphoprotein 2 (GOLPH2) is a novel bile acid-responsive modulator of oesophageal cell migration and invasion.British journal of cancer · 2015Article
- Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma.Therapeutic advances in gastroenterology · 2015Review
- A relation between cell cycle and intestinal metaplasia in oesophageal biopsies using optical and digital microscopy.Pathology oncology research : POR · 2015Article
- Article
- Biomarkers of Barrett's esophagus.World journal of gastrointestinal pathophysiology · 2014Review
- Comparison of cancer-associated genetic abnormalities in columnar-lined esophagus tissues with and without goblet cells.Annals of surgery · 2014Article
- Multi-colour FISH in oesophageal adenocarcinoma-predictors of prognosis independent of stage and grade.British journal of cancer · 2014Article
- Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma.Molecular biology reports · 2014Article
- Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Article
- Psychosocial factors and their association with reflux oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma.World journal of gastroenterology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Barrett's esophagus is a well-known premalignant lesion of the lower esophagus that is characterized by intestinal metaplasia of the squamous epithelium. It is clinically important due to the increased risk (0.5% per annum) of progression to esophageal adenocarcinoma (EA), which has a poor outcome unless diagnosed early. The current clinical management of Barrett's esophagus is hampered by the lack of accurate predictors of progression. In addition, when patients develop EA, the current staging modalities are limited in stratifying patients into different prognostic groups in order to guide the optimal therapy for an individual patient. Biomarkers have the potential to improve radically the clinical management of patients with Barrett's esophagus and EA but have not yet entered mainstream clinical practice. This is in contrast to other cancers like breast and prostate for which biomarkers are utilized routinely to inform clinical decisions. This review aims to highlight the most promising predictive and prognostic biomarkers in Barrett's esophagus and EA and to discuss what is required to move the field forward towards clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.